Sugi Predict

Sugi Predict / Compounds / SCHEMBL928009

SCHEMBL928009

SCHEMBL928009

COc1ccc(-c2ccc3ncc4c(c3c2)n(-c2ccc(N3CCNCC3)c(C(F)(F)F)c2)c(=O)n4C)cc1OC

nearest known ligand 0.82

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ MTOR P42345 16/20 0.82
▸ PIK3CA P42336 3/20 0.82
▸ PIK3CD O00329 2/20 0.82
▸ PIK3CB P42338 2/20 0.82
▸ PIK3CG P48736 2/20 0.82
▸ CSNK2A2 P19784 1/20 0.82
▸ FECH P22830 1/20 0.82
▸ CLK1 P49759 1/20 0.82
▸ GSK3A P49840 1/20 0.82
▸ DYRK1A Q13627 1/20 0.82
▸ MELK Q14680 1/20 0.82
▸ MYLK3 Q32MK0 1/20 0.82
▸ PIK3C3 Q8NEB9 1/20 0.82
▸ PIP4K2C Q8TBX8 1/20 0.82
▸ TP53RK Q96S44 1/20 0.82
▸ RPTOR Q8N122 1/20 0.74
▸ MLST8 Q9BVC4 1/20 0.74
▸ RIOK2 Q9BVS4 4/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Fumaric Acid SCHEMBL993841 0.94 MTOR (0.74) MTORPIK3CAPIK3CDPIK3CBPIK3CG
Maleic Acid SCHEMBL993840 0.94 MTOR (0.74) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL928292 0.91 MTOR (0.84) MTORPIK3CAPIK3CDPIK3CBPIK3CG
Bgt-226 Free Base SCHEMBL146939 0.90 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CBPIK3CG
Bgt-226 Free Base SCHEMBL29351405 0.90 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CBPIK3CG
Bgt-226 Free Base SCHEMBL29388607 0.90 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CBPIK3CG
Bgt-226 Free Base SCHEMBL29388241 0.90 MTOR (1.00) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL930075 0.89 MTOR (0.79) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL929491 0.89 MTOR (0.79) MTORPIK3CAPIK3CDPIK3CBPIK3CG
SCHEMBL927259 0.88 MTOR (0.78) MTORPIK3CAPIK3CDPIK3CBPIK3CG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2292617-A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors Novartis AG (CH) 2011-03-09 — — EP claimed
EP-2270008-A1 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinases inhibitors Novartis AG (CH) 2011-01-05 — — EP claimed
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2010-03-04 — — US claimed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 — — US claimed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 — — EP claimed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 — — WO claimed
US-9370508-B2 Imidazoquinolines as dual lipid kinase and mTOR inhibitors NOVARTIS AG (CH) 2016-06-21 — — US disclosed
EP-2624831-A1 PHARMACEUTICAL COMBINATIONS Novartis AG (CH) 2013-08-14 — — EP disclosed
US-20130178479-A1 PHARMACEUTICAL COMBINATIONS NOVARTIS AG (CH) 2013-07-11 — — US disclosed
US-8431592-B2 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2013-04-30 — — US disclosed
US-20120282252-A1 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes NOVARTIS AG (CH) 2012-11-08 — — US disclosed
EP-2270008-B1 8-heteroaryl-3-alkyl-1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as PI-3 kinases inhibitors NOVARTIS AG (CH) 2012-10-03 — — EP disclosed
US-20120207751-A1 Imidazoquinolines as lipid kinase inhibitors NOVARTIS AG (CH) 2012-08-16 — — US disclosed
US-7667039-B2 1,3-dihydro-imidazo [4,5-C] quinolin-2-ones as lipid kinase inhibitors NOVARTIS AG (CH) 2010-02-23 — — US disclosed
EP-2129379-A1 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS Novartis AG (CH) 2009-12-09 — — EP disclosed
WO-2009118324-A1 5IMIDAZOQUINOLINES AND PYRIMIDINE DERIVATIVES AS POTENT MODULATORS OF VEGF-DRIVEN ANGIOGENIC PROCESSES NOVARTIS AG (CH) 2009-10-01 — — WO disclosed
WO-2008103636-A1 IMIDAZOQUINOLINES AS DUAL LIPID KINASE AND MTOR INHIBITORS NOVARTIS AG (CH) 2008-08-28 — — WO disclosed
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors NOVARTIS AG (CH) 2008-08-14 — — US disclosed
EP-1888578-A2 IMIDAZOQUINOLINES AS LIPID KINASE INHIBITORS Novartis AG (CH) 2008-02-20 — — EP disclosed
WO-2006122806-A2 1,3-DIHYDRO-IMIDAZO [4,5-C] QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS NOVARTIS AG (CH) 2006-11-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100056558-A1 1,3-DIHYDRO-IMIDAZO[4,5-C]QUINOLIN-2-ONES AS LIPID KINASE INHIBITORS PDPK1, PI4KA, PIP4K2A MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885
US-20120207751-A1 Imidazoquinolines as lipid kinase inhibitors PI4KA, PDPK1, PI4KB MTOR 171/4885PIK3CA 29/4885PIK3CD 58/4885
US-20130178479-A1 PHARMACEUTICAL COMBINATIONS MTOR, RICTOR, PIK3CA MTOR 1/4885PIK3CA 3/4885PIK3CD 4/4885
US-20120282252-A1 5Imidazoquinolines and Pyrimidine Derivatives as Potent Modulators of VEGF-Driven Angiogenic Processes KDR, FLT4, TEK MTOR 2286/4885PIK3CA 1091/4885PIK3CD 1413/4885
US-20080194579-A1 1,3-Dihydro-Imidazo [4,5-C] Quinolin-2-Ones as Lipid Kinase Inhibitors PDPK1, PI4KA, PIP4K2A MTOR 89/4885PIK3CA 8/4885PIK3CD 9/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.